1. Scrip
  2. >>Business

M&A Analysis Reveals Mid Pharma Purchase Preferences

 
• By Sukaina Virji

Immunology- and inflammation-focused biotech companies wondering if a trade exit is in their future will be interested to read that, according to a report from Datamonitor Healthcare, their demographic is the most popular acquisition target of the mid-size pharma cohort.

Between 2011 and Q3 2016, Datamonitor Healthcare's nine-company Mid Pharma cohort inked 50 acquisitions and was responsible for about $200bn in up-front M&A value.

Historically, Datamonitor Healthcare's Mid Pharma peer set was defined as those companies with less than $10bn in annual revenue, excluding biotechs, generics companies, and Japanese pharmaceutical companies. However, the cohort...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

More from Scrip

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.